9th Circ. Keeps Investor Class Intact In Anemia Drug Fight
The Ninth Circuit refused on Tuesday to decertify a class of shareholders in a case alleging Amgen Inc. misled investors about two top-selling anemia drugs, ruling the suit plausibly alleged the...To view the full article, register now.
Already a subscriber? Click here to view full article